David H. Adams’s research while affiliated with Sinai Health System and other places

... The mean age of the patient was 78 years and 59% of them was woman. In this pivotal trial the primary composite endpoint was met but the results were primarily driven by improvements in quality of life associated with TR; this results were also confirmed at 1 year analysis of the full randomized cohort (572 patients) [22,23]. Similar data were corroborated from the bRIGHT registry [24]. ...

Reference:

Multimodality Imaging for Transcatheter Tricuspid Regurgitation Interventions: Novel Approaches to the Forgotten Valve

... Pericarditis is defined as inflammation of the pericardial sac containing the heart [1]. Pericarditis is a common cause of chest pain leading to numerous emergency room visits and require pericardiectomy [4]. In addition, transient constrictive pathophysiology should be quickly identified as it is a reversible form of constrictive pericarditis with ongoing inflammation without progression to chronic constriction. ...

Reference:

The Role of the Advanced Practice Provider in a Pericardial Center of Excellence

... Following the success of TAVR in patients with native AS, the use of TAVR as a valvein-valve (ViV) procedure has expanded to treating failed surgical or percutaneous valves. Non-randomized data have suggested promising 30-day and 1-year outcomes of ViV TAVR compared to traditional open redo SAVR in high-risk surgical candidates [64,65]. However, ViV TAVR is limited to patients with large enough annuli and carries a heightened risk of coronary obstruction. ...

Reference:

Transcatheter Aortic Valve Implantation and Replacement: The Latest Advances and Prospects

... The Intrepid valve is specifically designed for patients with mitral regurgitation (MR) and now also for tricuspid regurgitation. Following transcatheter mitral valve replacement using the transapical Intrepid valve, 99.5% (n=200) of patients had mild or less MR within 30 days, and all surviving patients (n=122) had mild or less MR at the 2-year followup [16]. A pre-market trial is currently underway (NCT03242642). ...

Reference:

Transcatheter Tricuspid Valve Replacement: will it take over? Review Article

... Approaches to promote myocardial recovery after cardiogenic shock. MCS: myocardial cardiogenic shock; IABP: intra-aortic balloon pump; LVAD: left ventricular assist device; TAVR: transcatheter aortic valve replacement; TEER: transcatheter edge-to-edge repair; SSO 2 : super-saturated oxygen; ECMO: extracorporeal membrane oxygenation; VT: ventricular tachycardia; GDMT: guideline-directed medical therapy to 10 years post explant, the outcomes of these patients post explant remain encouraging, including freedom from recurrent HF or need for advanced therapies.44,45 ...

Reference:

Myocardial Recovery in Cardiogenic Shock

... Therefore, prospective studies have mainly demonstrated an improvement in quality of life in patients treated by transcatheter tricuspid valve repair. 46 With a 2-year mortality of 22% in our analysis in the percutaneously managed patient, mortality rates align to those observed in the percutaneous group with intermediate TRISCORE (4 or 5) in the TRIGISTRY study (29%). 47 In this study, within this risk group category, successful percutaneous TR correction reduced mortality to 19% while unsuccessful correction was associated with a 66% 2-year mortality. ...

Reference:

Survival outcomes in isolated severe tricuspid regurgitation according to therapeutic modalities: a systematic review and meta-analysis

... In patients with MAC and MS, balloon-expandable transcatheter valves (BEVs) designed for the aortic valve can be implanted with MAC acting as an anchor. Dedicated TMVR devices such as Tendyne TM (Abbott, USA) and Intrepid TM (Medtronic, USA) valves are currently under assessment in MAC patients, with initial findings from the MAC subgroup already documented [40][41][42][43]. ...

Reference:

Rheumatic and Degenerative Mitral Stenosis: From an Iconic Clinical Case to the Literature Review

... Myxomatous degeneration includes a progressive series of degenerative diseases that expand from fibroelastic deficiency to Barlow syndrome; the latter, has as its main characteristic that of making the leaflets redundant with excessive volume and/or height, determining a retrograde blood flow in the left atrium during mid-late systole, associated with a significant variation in the observed left ventricular flow patterns. [5][6][7] However, recent studies suggest that nonmyxomatous inflammation and myocardial damage occur before the development of hemodynamically significant mitral regurgitation, 8 thus, encouraging further study of valve movement and its influence in different clinical scenarios. The recommended treatment for severe degenerative mitral valve regurgitation is surgical mitral valve repair (MV r ), the gold standard therapeutic procedure for patients with degenerative mitral valve regurgitation wich follows two fundamental principles: restore a good surface of leaflet coaptation and correct annular dilatation; 9,10 preferred to prosthetic replacement with a biological or mechanical valve due to the superior event-free survival following surgical repair. ...

Reference:

Modeling the fluid dynamics of mitral valve for clinical applications and surgical mitral valve repair

... Machine learning, a key AI and data science branch, uses algorithms to predict outcomes from historical data, with increasing medical applications in diagnosis and prognosis, highlighting this trend [14,15]. Outcome metrics are significantly impacted by various input variables, making it crucial to consider all relevant factors to enhance model performance [16]. At the same time, excluding variables that naturally influence outcomes is essential to avoid causality issues and maintain the model's external validity. ...

Reference:

Identification of Critical Risk Factors in CABG Surgery: A Survey-Based Expert Opinion Study

... It is desirable to leave the patient with as little PPM as possible after surgical aortic valve replacement (SAVR), but the risk-benefit ratio of avoidance of PPM should be individualized for each patient. 6 Recently, Dismorr et al 7 published the outcomes of patients undergoing SAVR in the Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART) registry. The authors concluded that moderate PPM was common but of negligible clinical significance, whereas the incidence of severe PPM was uncommon (3% of all SAVR) and associated with a 4.6% higher mortality at 10 years. ...

Reference:

Impact of Prosthesis-Patient Mismatch After Surgical Aortic Valve Replacement: Systematic Review and Meta-Analysis of Reconstructed Time-to-Event Data of 122 989 Patients With 592 952 Patient-Years